$エスペリオン セラピューティクス(ESPR.US)$Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity. Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.
The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.
Jazz Pharmaceuticals' low P/S ratio is due to slower revenue growth compared to industry trend, leading to discomfort amongst shareholders and stock devaluation. Persisting sluggish growth may decrease P/S ratio even further unless fortunes change.
Analyst Joon Lee supports the potential split of Jazz's businesses given its growing oncology unit and competitive CNS franchise, valuing Jazz at $200 per share. Alternatively, Jason Gerberry suggests selling the oncology unit and focusing on CNS or spin-off maybe more likely than a total sale, with a 'buy' rating and $217 price target remaining.
Seth Klarman’s 13F portfolio value decreased from $6.13B to $5.85B this quarter. Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com. The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio. New Stakes: $スカイワークス ソリューションズ(SWKS.US)$and$ジャズ ファーマシューティカルズ(JAZZ.US)$ Stake Disposals: $メタ プラットフォームズ A(META.US)$ ...
ジャズ ファーマシューティカルズに関するコメント
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Keep a watch on FTNT and AYX
$Activision Blizzard(ATVI.US)$ $バイオデクサ・ファーマシューティカルズ(BDRX.US)$ $カドレナル・セラピューティクス(CVKD.US)$ $イーストサイド ディスティリング(EAST.US)$ $イロックス・ファーマシューティカルズ(ELOX.US)$ $Freeline Therapeutics(FRLN.US)$ $フォーティネット(FTNT.US)$ $イルミナ(ILMN.US)$ $ジャズ ファーマシューティカルズ(JAZZ.US)$ $メットライフ(MET.US)$ $NanoString Technologies(NSTG.US)$ $ペインリフォーム(PRFX.US)$ $プレステージ・ウェルス(PWM.US)$ $Sientra(SIEN.US)$ $Vmware(VMW.US)$
Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com.
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
New Stakes:
$スカイワークス ソリューションズ(SWKS.US)$ and $ジャズ ファーマシューティカルズ(JAZZ.US)$
Stake Disposals:
$メタ プラットフォームズ A(META.US)$
...
まだコメントはありません